Scarica l'app Stockscreener
22.45
5.15%
-1.22
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$23.67
Aprire:
$24.24
Volume 24 ore:
917.21K
Relative Volume:
0.35
Capitalizzazione di mercato:
$1.22B
Reddito:
$27.10M
Utile/perdita netta:
$-24.31M
Rapporto P/E:
-27.05
EPS:
-0.83
Flusso di cassa netto:
$-33.33M
1 W Prestazione:
-9.18%
1M Prestazione:
-9.44%
6M Prestazione:
+170.48%
1 anno Prestazione:
+44.37%
Intervallo 1D:
$22.26
$24.36
Intervallo di 1 settimana:
$22.26
$25.45
Portata 52W:
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Nome
Capricor Therapeutics Inc
Settore
Industria
Telefono
(310) 358-3200
Indirizzo
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
22.45 | 1.29B | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-30 | Iniziato | Alliance Global Partners | Buy |
| 2025-06-26 | Iniziato | B. Riley Securities | Buy |
| 2025-05-20 | Iniziato | Roth Capital | Buy |
| 2024-10-21 | Iniziato | Piper Sandler | Overweight |
| 2024-05-17 | Iniziato | Oppenheimer | Outperform |
| 2024-01-05 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-26 | Downgrade | Maxim Group | Buy → Hold |
| 2018-01-26 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-13 | Ripresa | Rodman & Renshaw | Buy |
| 2016-07-06 | Ripresa | H.C. Wainwright | Buy |
| 2016-06-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
Breakout Move: Whats the profit margin of Capricor Therapeutics Inc2025 Bull vs Bear & Weekly Momentum Stock Picks - baoquankhu1.vn
Why Capricor Therapeutics Inc. stock could see breakout soonEarnings Growth Summary & Long-Term Capital Growth Strategies - mfd.ru
How cyclical is Capricor Therapeutics Inc.’s revenue streamWeekly Trend Summary & Long-Term Capital Growth Strategies - mfd.ru
Following Sarepta Woes, Others Look To Unlock the Next Chapter in DMD Treatment - BioSpace
(CAPR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50-Day Moving AverageTime to Sell? - MarketBeat
Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback - MSN
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
A Look At Capricor Therapeutics (CAPR) Valuation After Its New Shelf Registration Filing - Sahm
Phase III wins propel Capricor, Belite and DBV higher in December - BioWorld MedTech
TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Capric - GuruFocus
Capricor Therapeutics, Inc. (CAPR): Uncovering the 124.68% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Oppenheimer reiterates Outperform rating on Capricor stock, maintains $54 target - Investing.com Canada
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.7%Here's Why - MarketBeat
Does FDA’s No-New-Trial Stance on Deramiocel Shift the Bull Case for Capricor Therapeutics (CAPR)? - Sahm
Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50 Day Moving AverageShould You Sell? - MarketBeat
(CAPR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
A Look At Capricor Therapeutics (CAPR) Valuation As FDA Advances Review Of Deramiocel BLA - Sahm
FDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’ - MSN
Highs Report: Whats the profit margin of Capricor Therapeutics IncBull Run & Weekly Stock Breakout Alerts - baoquankhu1.vn
Capricor Therapeutics, Inc. (CAPR): Investor Outlook On Promising 110% Upside Potential - DirectorsTalk Interviews
CAPR stock slides after FDA requests more data for genetic disorder therapy — what does retail think? - MSN
CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February - TradingView — Track All Markets
Does FDA’s HOPE-3 Data Request Clarify Deramiocel’s Regulatory Path For Capricor Therapeutics (CAPR)? - Sahm
Is FDA’s No-New-Trial Stance on Deramiocel Reshaping the Investment Case for Capricor Therapeutics (CAPR)? - Yahoo Finance
Is Capricor Therapeutics (CAPR) Still Attractive After A 72% One Year Share Price Jump - Yahoo Finance
Capricor Updates Deramiocel BLA Status After FDA Review of HOPE-3 Data - filmogaz.com
Capricor Therapeutics (CAPR) Valuation After FDA Requests HOPE-3 Data For Deramiocel Regulatory Review - Yahoo Finance
Capricor (CAPR) Plans February FDA Data Submission After 2% Stock Drop - Intellectia AI
CAPR Stock Slides After FDA Requests More Data For Genetic Disorder Therapy — What Does Retail Think? - Stocktwits
FDA Requests Capricor To Submit HOPE-3 Clinical Study Report For Deramiocel BLA Review - RTTNews
Capricor Therapeutics Provides Regulatory Updates Regarding Its Biologics License Application for Deramiocel - marketscreener.com
Capricor Therapeutics (CAPR) Moves Forward with Regulatory Update on Cell Therapy - GuruFocus
Capricor Therapeutics Inc. Provides Regulatory Update on Deramiocel BLA Submission Following FDA Request for HOPE-3 Clinical Study Report - Quiver Quantitative
FDA asks for full HOPE-3 data on DMD cell therapy, no new trials - Stock Titan
Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving AverageHere's Why - MarketBeat
‘Pharma Bro’ Martin Shkreli Calls His Capricor Therapeutics Short A 'Bad Call' After DMD Trial Delivers Surprise Win - MSN
Capricor Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com UK
Cantor Fitzgerald reiterates Overweight rating on Capricor stock By Investing.com - Investing.com UK
A Look At Capricor Therapeutics (CAPR) Valuation After Deramiocel Phase 3 Success And Nippon Shinyaku Deals - Sahm
EV Market: Whats the profit margin of Capricor Therapeutics Inc2025 Major Catalysts & Smart Swing Trading Techniques - baoquankhu1.vn
Capricor Therapeutics (NASDAQ:CAPR) Cut to Sell at Wall Street Zen - MarketBeat
Why Capricor Therapeutics Inc. stock attracts high net worth investorsStock Surge & Risk Controlled Daily Plans - Улправда
Capricor Therapeutics: A High Risk/High Reward Name - Seeking Alpha
Why Capricor Therapeutics (CAPR) Is Down 15.8% After Phase 3 Win And $1.5 Billion Deal - simplywall.st
Here's Why This Biotechnology Skyrocketed by 439% in December - Yahoo Finance
How interest rate cuts could boost Capricor Therapeutics Inc. stockMarket Trend Summary & Real-Time Volume Spike Alerts - ulpravda.ru
Investment Recap: How interest rate cuts could boost Capricor Therapeutics Inc. stockJuly 2025 Reactions & Weekly Top Stock Performers List - ulpravda.ru
Can Capricor Therapeutics Inc. stock weather global recession2025 Geopolitical Influence & Technical Pattern Recognition Alerts - ulpravda.ru
Capricor Therapeutics, Inc.Common Stock (NQ: CAPR - FinancialContent
Capricor Therapeutics Inc Azioni (CAPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):